帕尼培南/倍他米隆治疗重症感染30例临床疗效及安全性分析  

Analysis of efficacy and safety of panipenem/betamipron in treatment of 30 patients with severe bacterial infection

作　　者：连江山[1] 刘薇[1] 黄建荣[1] 

机构地区：[1]浙江大学医学院附属第一医院感染科传染病诊治国家重点实验室,浙江杭州310003

出　　处：《中国微生态学杂志》2011年第3期239-240,共2页Chinese Journal of Microecology

基　　金：艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2008ZX10002-005)

摘　　要：目的探讨帕尼培南/倍他米隆治疗重症感染临床疗效及安全性。方法 30例临床诊断为重症感染的患者静脉应用帕尼培南/倍他米隆1.0 g/8 h,观察患者临床症状、体征转归及实验室指标变化。结果应用帕尼培南/倍他米隆治疗重症感染30例,痊愈15例,显效10例,死亡1例,总有效率达83.3%。细菌培养结果阳性16例,培养阳性率为53.3%,细菌清除率为88.8%,不良反应率为6.7%。结论帕尼培南/倍他米隆治疗重症感染有较好的临床疗效,不良反应率低。Objective To investigate the efficacy and safety of panipenem/betamipron initially used for severe bacterial infection patients. Method Patients clinically diagnosed with severe bacterial infection were treated with panipenem/betamipron,1.0 g intravenously once every eight hours. Result The effective rate of panipenem/betamipron used for severe bacterial infection patients was 83.3%;the bacterial eradication rate was 88.8%,and the adverse reaction rate was 6.7%. Conclusion Panipenem/betamipron is effective and safe in the treatment of patients with severe bacterial infection.

关 键 词：帕尼培南 倍他米隆 临床疗效 重症感染 

分 类 号：R978.1[医药卫生—药品]